Canton, Ohio: Steven Ochs, MD, a urologist with Urology One, recently performed Ohio’s first UroLift® System implant at Mercy Medical Center. Intended to treat symptoms of enlarged prostate, or benign prostatic hyperplasia (BPH), in men 50 years of age or older, the UroLift is the first permanent implant with the capability of quickly improving prostate function and urine flow rates while preserving sexual function.
Dr. Ochs believes the UroLift System is an excellent alternative to other BPH treatments, such as drug therapy or more invasive surgery.
“Studies have shown UroLift to be very safe and highly effective,” he says. “It provides fast, long-term relief from BPH symptoms with low risk of side effects, improving overall quality of life for my patients.”
About 37 million men in the United States have an enlarged prostate, a medical condition affecting the prostate gland that surrounds the male urethra. As men age, the prostate can become enlarged and gradually obstruct the urinary system.
“Medication often provides inadequate, temporary relief with side effects that can include sexual dysfunction, dizziness and headaches,” says Dr. Ochs. “Surgery – such as the transurethral resection of the prostate (TURP) – can be highly effective but also may leave patients with permanent side effects, such as urinary incontinence, erectile dysfunction and more. That’s why I have chosen to bring the UroLift System to Ohio. I believe it’s the best treatment option for BPH patients who qualify.”
“At Mercy, our long-standing mission of providing quality, compassionate care is why we strive to bring the latest technology with the best outcomes to the communities we’ve served since 1908,” says Tom Cecconi, Mercy president and CEO. “UroLift and its benefits over current BPH treatments epitomizes the kind of options we want to make accessible to our patients.”
Developed by medical device company NeoTract and cleared by the U.S. Food and Drug Administration in 2013, the UroLift System’s permanent implants, which are delivered during a minimally-invasive procedure, act like window curtain tie-backs to hold the lobes of an enlarged prostate open. Patients recover from the procedure quickly, and return to their normal routines with minimal downtime. Data from clinical trials showed patients receiving UroLift implants reported rapid symptomatic improvement, improved urinary flow rates, and sustained sexual function. Patients also experienced a significant improvement in quality of life.
To learn more about the UroLift System in Stark County, Ohio, and surrounding areas, contact Urology One at 330-456-6760.
About the UroLift System
The FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia and Canada. Learn more at http://www.UroLift.com.
NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.Please click here for media inquiries